HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV)

HC Wainwright reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.28 EPS.

Separately, Ascendiant Capital Markets cut their price objective on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock opened at $1.19 on Friday. Plus Therapeutics has a one year low of $1.15 and a one year high of $2.67. The company has a market capitalization of $7.02 million, a PE ratio of -0.47 and a beta of 0.69. The company has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $1.66.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics as of its most recent SEC filing. 3.28% of the stock is owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.